Hanson, Rachel L. W. http://orcid.org/0000-0002-2569-9810
Airody, Archana
Sivaprasad, Sobha
Gale, Richard P.
Funding for this research was provided by:
Novartis | Novartis Pharmaceuticals UK Limited (OAP030A2401T)
Article History
Received: 7 July 2022
Revised: 13 October 2022
Accepted: 6 December 2022
First Online: 16 December 2022
Competing interests
: RPG has received honorarium for advisory board meetings and speaker fees from Abbvie, Allergan, Alimera, Apellis, Bayer, Heidelberg Engineering, Lux Biosciences, Novartis, Notal Vision and Roche, and has been awarded institutional grants from Novartis Pharmaceuticals UK Ltd and Bayer Pharmaceuticals. SS has been awarded institutional research grants and received support for publication from Novartis, Bayer, Allergan/Abbvie and Boehringer Ingleheim, S.S. also attended advisory board meetings of Allergan, Apellis, Bayer, Boehringer Ingelheim, Heidelberg Engineering, Novartis, Oxurion, Oculis, Optos, Ophthea, Roche.